argenx SE | ARGX - Cash And Equivalent

Stock Price
680.20
Daily Change
-13.00 -1.88%
Monthly
-3.87%
Yearly
34.16%
Q2 Forecast
678.23

argenx SE reported $4.3B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AstraZeneca USD 7.56B 1.85B Mar/2026
Genmab DKK 1.72B 46M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 801M 242.31M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Qiagen NV USD 839M 516.58M Dec/2025
UCB EUR 1.57B 1.14B Dec/2024